Opioid Sparing Multimodal Analgesia in Enhanced Recovery After Surgery Protocols A comprehensive Review

Abstract

Postoperative pain management remains a critical component of surgical care, yet traditional opioid-centric approaches have contributed to widespread adverse effects, including the ongoing opioid epidemic. Enhanced Recovery After Surgery (ERAS) protocols represent a paradigm shift toward multimodal, patient-centered perioperative care designed to minimize surgical stress, accelerate recovery, and reduce complications. Central to these protocols is opioid-sparing multimodal analgesia (MMA), which integrates pharmacological agents, regional anesthesia techniques, and non-pharmacological interventions to target diverse pain pathways while minimizing opioid reliance. This narrative review synthesizes current evidence on opioid-sparing strategies within ERAS frameworks, drawing from meta-analyses, randomized controlled trials (RCTs), and guidelines from bodies like the ERAS Society and American Society of Anesthesiologists (ASA). Key pharmacological agents discussed include acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), gabapentinoids, alpha-2 agonists (e.g., dexmedetomidine), N-methyl-D-aspartate (NMDA) antagonists (e.g., ketamine), and lidocaine infusions. Regional techniques such as epidural analgesia, transversus abdominis plane (TAP) blocks, and peripheral nerve blocks are highlighted for their synergistic effects. Evidence across surgical specialties—abdominal, thoracic, orthopedic, urologic, and head and neck—demonstrates reductions in postoperative opioid consumption, pain scores, postoperative nausea and vomiting (PONV), hospital length of stay (LOS), and complications, though benefits vary by procedure and patient factors. Challenges include hemodynamic risks from certain agents, implementation barriers in ambulatory settings, and the need for personalized approaches in high-risk populations (e.g., chronic opioid users or those with comorbidities). Future directions emphasize artificial intelligence (AI)-driven risk prediction, objective pain assessment tools, and large-scale RCTs to refine protocols. By prioritizing opioid-sparing MMA, ERAS pathways not only enhance immediate recovery but also mitigate long-term risks like chronicpostsurgical pain (CPSP) and opioid dependency, aligning with broader public health goals. This review underscores the evolution from opioid-dominant to balanced, evidence-based analgesia, offering implications for clinical practice, education, and policy.

Keywords

Introduction

The landscape of perioperative care has undergone significant transformation over the past three decades, driven by the need to optimize patient outcomes amid rising surgical volumes and escalating healthcare costs. Traditional postoperative pain management, heavily reliant on opioids, has been associated with a myriad of complications, including respiratory depression, ileus, PONV, opioid-induced hyperalgesia (OIH), and the risk of long-term dependency. These issues are particularly pronounced in the context of the global opioid epidemic, where surgical prescriptions contribute substantially to misuse and addiction. In the United States alone, postoperative opioids account for a significant portion of initial exposures leading to chronic use, with estimates suggesting that up to 80% of surgical patients experience inadequate pain control under opioid-monotherapy regimens. This has prompted a reevaluation of analgesic strategies, culminating in the adoption of Enhanced Recovery After Surgery (ERAS) protocols [1,2]. ERAS, first conceptualized in the 1990s by Danish surgeon Henrik Kehlet as "fast-track" surgery, evolved into a formalized multidisciplinary framework by the ERAS Society in 2001. These protocols encompass over 20 evidence-based elements spanning preoperative, intraoperative, and postoperative phases, aimed at reducing physiological stress, promoting early mobilization, and expediting recovery. Core principles include preoperative patient education, nutritional optimization, minimized fasting with carbohydrate loading, goal-directed fluid therapy, and early postoperative feeding and ambulation. However, pain management is pivotal, as uncontrolled pain impedes mobility, delays discharge, and heightens complication risks. Within ERAS, opioid-sparing multimodal analgesia (MMA) emerges as a cornerstone, combining multiple agents and techniques to act synergistically on nociceptive pathways—transduction, transmission, modulation, and perception—while curtailing opioid exposure.[3,4]Opioid-sparing approaches can be categorized into opioid-minimizing (opioid-sparing analgesia, OSA) and opioid-eliminating (opioid-free analgesia, OFA) strategies. OSA integrates low-dose opioids as rescue therapy, whereas OFA relies entirely on non-opioids, regional blocks, and adjuncts. Evidence from narrative reviews and meta-analyses indicates that these methods reduce opioid consumption by 20-50%, lower PONV incidence (odds ratio [OR] 0.27-0.55), and improve quality of recovery (QoR) scores without compromising analgesia in many cases. Yet, nuances exist: OFA may excel in ambulatory or minor procedures but requires careful patient selection to avoid intraoperative instability, such as bradycardia from alpha-2 agonists.[3,4]This narrative review explores opioid-sparing MMA within ERAS protocols from multiple angles, including historical context, mechanistic underpinnings, specific interventions, clinical evidence across specialties, implementation challenges, and future implications. By examining edge cases—such as chronic opioid users, elderly patients, or those with comorbidities—and related considerations like cost-effectiveness and educational gaps, this review aims for completeness. Drawing on sources up to 2025, it highlights how these strategies not only enhance immediate postoperative outcomes but also address broader societal issues like opioid diversion and chronic pain prevention. The discussion is structured to provide clinicians, researchers, and policymakers with a comprehensive framework for integrating opioid-sparing analgesia into routine practice.[3,4]

Overview of ERAS Protocols

Enhanced Recovery After Surgery protocols represent a holistic, evidence-based approach to perioperative care, initially developed for colorectal surgery but now adapted to over 20 specialties, including orthopedics, gynecology, urology, and cardiothoracic procedures. The ERAS Society guidelines emphasize multidisciplinary collaboration among surgeons, anesthesiologists, nurses, and allied health professionals to standardize care and audit outcomes. Key preoperative elements include patient counseling to set expectations, screening for psychosocial risks (e.g., anxiety via Hospital Anxiety and Depression Scale [HADS] or pain catastrophizing via Pain Catastrophizing Scale [PCS]), nutritional assessment to address deficiencies, and carbohydrate loading (e.g., 800 mL of 12.5% carbohydrate solution 2-4 hours preoperatively) to mitigate insulin resistance and catabolism.[4,5]Intraoperatively, ERAS advocates for minimally invasive techniques, short-acting anesthetics, normothermia maintenance, and goal-directed fluid therapy to avoid overload or hypovolemia. Postoperative strategies focus on early oral intake, mobilization within 24 hours, and removal of catheters/drains to prevent complications like urinary retention or infection. Pain management is interwoven throughout, with opioid-sparing MMA as a foundational pillar. For instance, in orthopedic ERAS for hip/knee replacements, protocols incorporate atraumatic surgery, multimodal opioid-sparing regimens, and early ambulation to reduce LOS by 1-3 days.[5]Implementation of ERAS has demonstrated consistent benefits: a meta-analysis of colorectal pathways showed 2.5-day reductions in LOS, 50% lower complication rates, and cost savings of $1,000-5,000 per patient. However, adherence varies, with barriers including institutional resistance, resource limitations, and variability in pain protocols. In ambulatory settings, ERAS adaptations emphasize same-day discharge, leveraging opioid-sparing techniques to minimize readmissions for pain or nausea. Edge cases, such as emergency surgeries or patients with severe comorbidities (e.g., diabetes or obesity), require tailored modifications, like enhanced glycemic control or adjusted fluid goals, to balance recovery acceleration with safety.[6]The integration of opioid-sparing analgesia within ERAS is not merely additive but synergistic, as reduced opioid side effects (e.g., ileus) facilitate other elements like early feeding. ERAS Society guidelines explicitly recommend multimodal regimens, including nonopioids and regional blocks, to minimize opioids across phases. This approach has evolved from early opioid-dominant models to contemporary frameworks prioritizing prevention of chronic pain and dependency, reflecting a shift toward patient-centered, value-based care.[6]

The Opioid Epidemic and Rationale for Opioid-Sparing Approaches

The opioid crisis, declared a public health emergency in the U.S. in 2017, has roots in overprescription, with surgical interventions contributing 80% of new persistent users among opioid-naive patients. Globally, opioid-related deaths exceed 100,000 annually, amplified by postoperative prescriptions that often exceed needs—leading to diversion and misuse. In surgical contexts, opioids exacerbate complications: respiratory depression affects 1-11.5% of patients, PONV occurs in 30-50%, and OIH increases pain sensitivity, prolonging recovery.[7]Opioid-sparing strategies address these by targeting multiple pain mechanisms, reducing total morphine equivalents (MMEs) by 10-15 mg in the first 24 hours postoperatively. Rationale includes physiological benefits—opioids suppress gastrointestinal motility via mu-receptors, delaying bowel recovery by 24-48 hours, whereas nonopioids preserve function. Psychosocially, opioids heighten addiction risk in vulnerable groups (e.g., those with depression or substance history), with 6-10% of surgical patients developing new chronic use.In ERAS, opioid-sparing mitigates these risks while enhancing outcomes. For example, in gynecologic oncology, ERAS reduced discharge opioids by 72%, with no increase in pain scores. Nuances include procedure-specific risks: thoracic surgeries face higher OIH due to nerve involvement, while ambulatory procedures benefit from OFA to enable same-day discharge. Edge cases like chronic opioid users (64-77% persist postoperatively) require transitional pain services for weaning, integrating behavioral therapies to prevent escalation.[8]

Principles of Multimodal Analgesia

Multimodal analgesia operates on the premise that pain is multifaceted, involving peripheral sensitization, central modulation, and descending inhibition. By combining agents with complementary mechanisms, MMA achieves synergy, allowing lower doses and fewer side effects than monotherapies. Core principles include preemptive analgesia (administering agents before incision to prevent central sensitization), balanced regimens targeting nociceptive and neuropathic components, and patient-specific tailoring based on comorbidities, pain history, and surgical type.[9]In ERAS, MMA is phased: preoperative (e.g., acetaminophen to reduce early pain), intraoperative (e.g., infusions for stability), and postoperative (scheduled nonopioids with rescue opioids). Evidence from meta-analyses shows MMA reduces 24-hour pain scores by 0.6-1.0 on visual analog scale (VAS) and opioids by 4-14 mg MMEs. Nuances: in inflammatory-dominant pain (e.g., orthopedic), NSAIDs excel; in neuropathic (e.g., thoracic), gabapentinoids are key. Considerations include pharmacokinetics—e.g., IV vs. oral routes for faster onset—and interactions (e.g., NSAIDs with anticoagulants increasing bleed risk). Edge cases: pediatric patients require weight-based dosing to avoid toxicity; elderly face polypharmacy risks, necessitating renal/hepatic adjustments. Implications for ERAS include improved compliance with mobilization, as MMA minimizes sedation, fostering a cycle of enhanced recovery.[10]

Pharmacological Agents in Opioid-Sparing Regimens

Acetaminophen and NSAIDs

Acetaminophen, a central prostaglandin inhibitor, is foundational in MMA, reducing pain and opioids short-term (up to 2 hours preoperatively). Dosing: 1 g IV or oral pre/intraoperatively, with benefits in reducing PONV when combined with NSAIDs. NSAIDs (e.g., ibuprofen, ketorolac) block peripheral cyclooxygenase, decreasing inflammation and MMEs by 10 mg/24 hours. In orthopedics, low-dose NSAIDs show no significant non-union risk, per meta-analyses. However, GI surgeries pose anastomotic leak risks, limiting use; alternatives like selective COX-2 inhibitors (celecoxib) mitigate this. Benefits: Synergistic with other agents, reducing opioid side effects. Risks: Renal impairment in dehydrated patients, platelet inhibition. Examples: In colorectal ERAS, acetaminophen-NSAID combos shorten LOS by 1 day. [11]

Gabapentinoids

Gabapentin and pregabalin bind voltage-gated calcium channels, reducing central sensitization. Preoperative dosing (gabapentin 600-1200 mg 2 hours prior) cuts PACU opioids in breast surgery but shows mixed long-term results. Meta-analyses confirm opioid-sparing (4-14 mg MMEs) and pain reduction, especially in high-risk groups, but side effects include sedation and respiratory depression at high doses. Nuances: Better for neuropathic pain; avoid in elderly due to dizziness. Implications: In ERAS for joint replacements, they enhance early ambulation.[12]

Alpha-2 Agonists

Dexmedetomidine provides sedation, analgesia, and sympatholysis without respiratory depression. Infusions (0.2-0.7 mcg/kg/h) spare opioids by 14.5 mg, per meta-analyses, and accelerate GI recovery. Clonidine is similar but with more hypotension. In cardiac ERAS, it reduces extubation time. Risks: Bradycardia (number needed to harm [NNH] ≈3), prolonged sedation. Edge cases: Contraindicated in bradycardic patients; titrate in obese.[13]

NMDA Antagonists

Ketamine (0.15-0.5 mg/kg) counters OIH, reducing opioids in chronic users post-spinal fusion. Subanesthetic doses improve pain quality in high-pain scenarios. Magnesium enhances this via NMDA blockade. Benefits: Opioid-tolerant patients; no psychotomimetic effects with low doses. Examples: In abdominal ERAS, ketamine shortens bowel recovery.[14]

Lidocaine Infusions

IV lidocaine (1-2 mg/kg/h) offers anti-inflammatory and anti-hyperalgesic effects, shortening hospital stays in abdominal surgery. Meta-analyses link to faster GI function and reduced nausea. Risks: Potential vasoactive effects; monitor for toxicity. Integration: Combined with dexmedetomidine in OFA.[15]

Other Adjuncts

Glucocorticoids (dexamethasone ≥15 mg) reduce PONV (OR 0.29) and MMEs by 10 mg, but cause hyperglycemia in diabetics. Muscle relaxants and antidepressants (e.g., duloxetine) target descending modulation.[15]

Regional Anesthesia Techniques

Regional techniques are integral to opioid-sparing ERAS, providing site-specific analgesia. Neuraxial blocks (e.g., continuous thoracic epidural analgesia [CTEA] with bupivacaine for abdominal surgery) reduce opioids and pain beyond duration via preventive effects. Meta-analyses favor CTEA over PCA in colorectal procedures, shortening LOS.[16]Peripheral blocks: TAP for abdominal, paravertebral for thoracic/breast, pectoral for mastectomy. Liposomal bupivacaine extends duration to 72 hours, reducing opioids in breast reconstruction. Ultrasound guidance minimizes complications like systemic toxicity. Benefits: Synergy with systemic MMA; reduced ileus. Risks: Infection, hematoma in anticoagulated patients. Edge cases: Obese patients require adjusted dosing; ambulatory use with catheters enables home management. In urologic ERAS, blocks like rectus sheath reduce PONV and stays. Implications: Facilitate early mobilization, crucial for ERAS success.[17]

Non-Pharmacological Interventions

Non-pharmacological methods complement MMA, addressing emotional and sensory pain aspects. Transcutaneous electrical nerve stimulation (TENS) and acupuncture reduce chronic pain signals; meta-analyses show postoperative benefits in orthopedics. Cognitive-behavioral therapy (CBT), mindfulness, and music therapy mitigate catastrophizing, improving satisfaction.Physical therapy, icing, and early mobilization prevent deconditioning. In ERAS, these integrate with pharmacological strategies, reducing opioids in ambulatory settings.Nuances: Limited evidence for cryoneurolysis; cultural preferences influence adoption. Edge cases: Psychiatric comorbidities benefit most from CBT. Implications: Cost-effective, low-risk enhancements to recovery.[18,19]

Evidence from Clinical Studies and Meta-Analyses

Abdominal and Colorectal Surgery

Meta-analyses (26 RCTs, 2,025 patients) show OFA reduces PONV (RR 0.55) with modest pain benefits. In ERAS, MMA shortens GI recovery and LOS by 1-2 days. [20]

Orthopedic Surgery

In joint replacements, OSA/OFA lowers pain and complications; low-dose NSAIDs safe for healing.[21]

Urologic Surgery

ERAS with blocks and ketamine reduces opioids and PONV in cystectomy/prostatectomy.

Head and Neck Surgery

MMA in free flap reconstruction lowers pain scores and narcotics.

Overall, meta-analyses confirm reduced MMEs (6-10 mg), PONV, and higher satisfaction, though heterogeneous. Edge cases: Chronic users show less benefit, requiring transitional services.

Integration within ERAS Protocols

Opioid-sparing MMA aligns with ERAS by enabling other elements: reduced ileus supports early feeding, less sedation aids mobilization. Guidelines recommend phased regimens, with audits for optimization. In cardiac ERAS, ketamine/dexmedetomidine protocols reduce ICU time.[23]

Challenges, Barriers, and Safety Considerations

Implementation barriers include clinician variability, educational gaps (e.g., limited training in blocks), and resource constraints. Safety: Alpha-2 agonists cause bradycardia; NSAIDs renal risks in elderly. Personalized approaches via preoperative screening mitigate these. Edge cases: Opioid-tolerant patients risk withdrawal; cultural differences affect opioid perceptions. Implications: Multidisciplinary teams and simulations address gaps.[24,25]

FUTURE DIRECTIONS AND RESEARCH NEEDS

AI for pain prediction, objective tools (e.g., fMRI), and RCTs on long-term outcomes (6-12 months) are needed. Refine agents (e.g., lidocaine dosing), expand to emergencies, and integrate psychiatric interventions.

REFERENCES

1. Wick EC, Grant MC, Wu CL. Postoperative multimodal analgesia pain management with nonopioid analgesics and techniques: A review. JAMA Surg. 2017;152(7):691–7.
2. Sun EC, Darnall BD, Baker LC, Mackey S. Incidence of and risk factors for chronic opioid use among opioid-naive patients in the postoperative period. JAMA Intern Med. 2016;176(9):1286–93.
3. Kehlet H. Multimodal approach to control postoperative pathophysiology and rehabilitation. Br J Anaesth. 1997;78(5):606–17.
4. ERAS® Society. Guidelines. 2025 [cited 2026 Jan 22]. Available from: https://erassociety.org/guidelines/
5. Thorell A, Soop M. Multimodal analgesia in enhanced recovery after surgery. World J Gastrointest Oncol. 2023;8(7):543.
6. Battaglia MA, Albright JJ, Wu J, et al. Liposomal bupivacaine in enhanced recovery after surgery. Clinics. 2018;58(2):34-41.
7. Englesakis MF, Kehlet H, Chan VW. Role of opioid-sparing analgesia in ERAS pathways. Pain Med. 2022;47(5):282-92.
8. Simon HL, Miller LK, Keller DS. A randomized controlled trial examining the impact of enhanced recovery after surgery protocol. World J Gastrointest Oncol. 2020;8(7):543.
9. Ghai B, Jafra A, Bhatia N, et al. Opioid sparing strategies for perioperative pain management other than regional anaesthesia: a narrative review. J Anaesthesiol Clin Pharmacol. 2022;38(1):3–10.
10. Qureshi I, Abdulrashid K, Thomas SH, et al. Comparison of intravenous paracetamol (acetaminophen) to intravenously or intramuscularly administered non-steroidal anti-inflammatory drugs (NSAIDs) or opioids for patients presenting with moderate to severe acute pain conditions to the ED: systematic review and meta-analysis. Emerg Med J. 2023;40(7):499–508.
11. Freo U. Paracetamol for multimodal analgesia. Pain Manag. 2022;12(6):737–50.
12. Tubog TD, Harmer CM, Bramble RS, et al. Efficacy and safety of gabapentin on postoperative pain management after bariatric surgery: a systematic review and meta-analysis. J Perianesth Nurs. 2023;38(2):322–30.
13. Lauretta MP, Marino L, Bilotta F. Safety and efficacy of opioid-sparing anesthesia compared with traditional opioid anesthesia: a scoping review. Clin J Pain. 2025;41(2):e1261.
14. Chen L, He W, Liu X, et al. Application of opioid-free general anesthesia for gynecological laparoscopic surgery under ERAS protocol: a non-inferiority randomized controlled trial. BMC Anesthesiol. 2023;23(1):34.
15. Wang Q, Zhang W, Xiao T, et al. Efficacy of opioids in preemptive multimodal analgesia for total knee arthroplasty: a prospective, double-blind, placebo-controlled, randomized trial. J Arthroplasty. 2023;38(1):65–71.
16. Chan TCW, Wong JSH, Wang F, et al. Addition of liposomal bupivacaine to standard bupivacaine versus standard bupivacaine alone in the supraclavicular brachial plexus block: a randomized controlled trial. Anesthesiology. 2024;141(4):732–744.
17. Morgan TH, Harloff M, et al. Efficacy of opioid-sparing analgesia after median sternotomy with continuous bilateral parasternal subpectoral plane blocks. J Thorac Cardiovasc Surg. 2024;167(6):2157-2169.
18. Strumia A, Pascarella G, Sarubbi D, et al. Rectus sheath block added to parasternal block may improve postoperative pain control and respiratory performance after cardiac surgery: a superiority single-blinded randomized controlled clinical trial. Reg Anesth Pain Med. 2024.
19. Davis AC, Voelkel JL, Remmers CL, et al. Role of regional anesthesia and analgesia in enhanced recovery after colorectal surgery: a systematic review of randomized controlled trials. Reg Anesth Pain Med. 2022;47(5):282–292.
20. Loria CM, Zborek K, Millward JB, et al. Enhanced recovery after cardiac surgery protocol reduces perioperative opioid use. J Cardiothorac Vasc Anesth. 2023;37:1179–1187.
21. Wang Q, Zhang W, Xiao T, Wang L, Ma T, Kang P. Efficacy of opioids in preemptive multimodal analgesia for total knee arthroplasty: a prospective, double-blind, placebo-controlled, randomized trial. J Arthroplasty. 2023;38(1):65–71.
22. Eisenbraun A, Schroeder D, Schaff HV, Martin E, Wittwer ED. Single-center retrospective comparison of opioid-based and multimodal analgesic regimens in adult cardiac surgery. J Cardiothorac Vasc Anesth. 2023;37:1179–1187.
23. ERAS® Society. Anaesthesia role in enhanced recovery after surgery: a revolution in care outcomes. Curr Opin Anaesthesiol. 2023;36(2):123–30.
24. Markham T, Wegner R, Hernandez N, Lee JW, Choi W, Eltzschig HK. Assessment of a multimodal analgesia protocol to allow the implementation of enhanced recovery after cardiac surgery: retrospective analysis of patient outcomes. BMJ Open Qual. 2021;10:e001320.
25. Clinical practice guidelines for postoperative pain management in adults (2024 edition). ScienceDirect; 2025. Available from: https://www.sciencedirect.com/science/article/pii/S2957391225000361